Lundbeck’s investigational oral orexin 2 receptor agonist gains Fast Track status, aiming to address underlying pathophysiology in patients with narcolepsy.

One in about 7300 individuals in the general population have PMS, a rare genetic condition that causes medical, intellectual, and behavioral challenges.

For patients aged 4 to 66 years with acquired hypothalamic obesity, setmelanotide leads to significantly greater reductions ...